Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients (2 to 11 years) with atopic dermatitis.
Dr. Cameron discusses promising results in a treatment that combined upadacitinib and topical corticosteroids. Reference:
...